Riboxx, CNBG unite in collaboration

RADEBEUL, Germany—A research collaboration has beenannounced between Riboxx Pharmaceuticals GmbH and China National Biotec GroupCo. Ltd. (CNBG) to evaluate Riboxxim, Riboxx's TLR3 agonist, with an antigenfrom CNBG against an undisclosed infectious disease target. Under the terms ofthe collaboration, Riboxx will provide access to the compound while CNBGevaluates it in conjunction with its antigen against the disease target.